

III CANCER CELL SIGNALING PATHWAYS CONFERENCE


LIQUID BIOPSY: THE ELBA PROGRAM



Germans Trias i Pujol Research Institute (IGTP), edifici Mar
Sala Polivalent
Badalona, Barcelona, Spain - July 19th, 2018

Organized by: Rafael Rosell, Imane Chaib, Maria Gonzalez-Cao and Niki Karachaliou

Graphical Abstract



Rafael Rosell, Trever G Bivona, Niki Karachaliou

Lancet 2013; 382: 720-31

Highlights:

Co-activation of receptor tyrosine kinases and non-receptor tyrosine kinases is a common feature in cancer. Cross-talk between different signaling pathways is the basis for poly-therapy in several tumors. Rewiring of cell signals occurs as a response to therapy.

PROGRAM

08:30: Welcome

8:45 ó 9:00: Origins of cancer: Cancer as a transmissible disease

- **Rafael Rosell**, *Cancer Biology & Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Research Institute and Hospital, Badalona, Spain*

SESSION I

Chairpersons: **Carles Codony, Imane Chaib**

9:00 ó 9:15: Cutting edge research in head and neck squamous cell carcinoma

- **Imane Chaib**, *Cancer Biology & Precision Medicine Program, Germans Trias i Pujol Research Institute, Badalona*

9:15 ó 9:30: Cancer stem cell markers used as adverse prognostic in NSCLC

- **Jordi Codony**, *Pangaea Oncology, Barcelona*

9:30 ó 9:45: Significance of Cellular Alkaline Phosphatase Activity in Human Leukemia

- **Jordi Petríz**, *Josep Carreras Leukaemia Research Institute (IJC), Badalona*

9:45 ó 10:00: EGF-PTI immunization in KRAS and ALK positive NSCLC

- **Silvia Garcia Roman**, *Pangaea Oncology, Barcelona*

10:00 ó 10:15: HSP90 inhibitor enhances antitumoral effect of osimertinib in NSCLC cell lines

- **Jordi Codony**, *Pangaea Oncology, Barcelona*

10:15 ó 10:30: MET inhibitors and mechanisms of resistance

- **Niki Karachaliou**, *IOR, Hospital Sagrat Cor and Coyote Research Group, Pangaea Oncology, Barcelona*

SESSION II

Chairpersons: **Niki Karachaliou, Imane Chaib**

10:30 ó 10:45: A-to-I RNA editing

- **Carlos Pedraz Valdunciel**, *Cancer Biology & Precision Medicine Program, Germans Trias i Pujol Research Institute, Badalona*

10:45 ó 11:00: A-to-I editing in microRNAs

- **Martyna Filip ska**, *Cancer Biology & Precision Medicine Program, Germans Trias i Pujol Research Institute, Badalona*

11:00 ó 11:15: Extracellular vesicle-mediated crosstalk in cancer

- **Jordi Berenguer**, *Coyote Research Group, Pangaea Oncology, Barcelona*

11:15 ó 11:30: Urine and plasma exosomes for early cancer detection, monitoring targeted therapy and immunotherapy

- **Jill Bracht**, *Coyote Research Group, Pangaea Oncology, Barcelona*

11:30 ó 11:45: State of art NSCLC

- **Santiago Viteri**, *IOR, Quiron-Dexeus Hospital, Barcelona, Spain*

11:45 ó 12:00: Immune research in NSCLC

- **Niki Karachaliou**, IOR, *Hospital Sagrat Cor and Coyote Research Group, Pangaea Oncology, Barcelona*

12:00 ó 12:15: DISCUSSION

SESSION III

Chairpersons: **Eloisa Jantus, Jose Luis Ramirez**

12:15 ó 12:30: NSCLC: leading approaches in liquid biopsy and patient`s derived *in vitro* models

- **Eloisa Jantus**, *Fundación para la Investigación, Hospital General Universitario de Valencia*

12:30 ó 12:45: NGS in circulating DNA

- **Núria Jordana and Mónica Garzón**, *Pangaea Oncology, Barcelona*

12:45 ó 13:00: ARID1A codriver mutations in plasma of lung adenocarcinoma patients

- **Niki Karachaliou**, IOR, *Hospital Sagrat Cor and Coyote Research Group, Pangaea Oncology, Barcelona*

13:00 ó 13:15: Applicability of Digital PCR in liquid biopsy

- **Jose Luis Ramirez**, *Cancer Biology & Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Badalona*

13:15 ó 13:30: Gene fusion analysis by Nano Counter

- **Miguel Angel Molina**, *Pangaea Oncology, Barcelona*

13:30 ó 14:10: LUNCH

SESSION IV

Chairpersons: **Carles Codony, Masaoki Ito**

14:10 ó 14:25: Immunotherapy for lung cancer - the clinician's perspective

- **Nuno Gil**, *Champalimaud Cancer Center for the Unknown, Lisbon, Portugal*

14:25 ó 14:40: KRAS mutations in NSCLC: synthetic lethal approaches

- **Carles Codony**, *Pangaea Oncology, Barcelona*

14:40 ó 14:55: miRNAs in exosomes

- **Martyna Filipaska**, *Cancer Biology & Precision Medicine Program, Germans Trias i Pujol Research Institute, Badalona*

14:55 ó 15:10: Targeting PKC -PAK1 signaling pathways in EGFR and KRAS mutations in NSCLC and squamous cell lung cancers

- **Masaoki Ito**, *Coyote Research Group, Pangaea Oncology, Barcelona*

15:10 ó 15:25: Commentaries on Masaoki Ito's presentation:

-miR-662, a target of PAK1 - **Martyna Filipiska**

-Relevance of inhibiting maternal embryonic leucine zipper kinase pathway (MELK)

-**Niki Karachaliou**

SESSION V

Chairpersons: **Luis Montuenga, Santiago Ramon y Cajal**

15:30 ó 15:50: Beyond molecular tumor heterogeneity: protein synthesis takes control

- **Santiago Ramón y Cajal**, *Pathology Dept. Vall d'Hebron University Hospital, Barcelona*

15:50 ó 16:10: The quest for lung cancer biomarkers in the context of screening: promises and challenges

- **Luis M. Montuenga**, *Center for Applied Medical Research, CIMA, Pamplona*

16:10 ó 16:25: Connexins and cell signaling in cancer: more than gap junctions

- **Trond Aasen**, *Pathology Translational Group, Vall d'Hebron University Hospital, Barcelona*

16:25 ó 16:40: Cancer diagnosis by machine learning-powered RNA-seq of tumor-educated platelets

- **Jordi Berenguer**, *Coyote Research Group, Pangaea Oncology, Barcelona*

16:40 ó 16:55: Immunotherapy in HIV positive cancer patients

- **Maria Gonzalez Cao**, *IOR, Quiron-Dexeus Hospital, Barcelona*

16:55 ó 17:10: The CRISPR way to think about cancer

- **David Llige**, *Cancer Biology & Precision Medicine Program, Germans Trias i Pujol Research Institute, Badalona*

17:10 ó 17:25: European Liquid Biopsy Academy (ELBA)

- **Niki Karachaliou**, *IOR, Hospital Sagrat Cor and Coyote Research Group, Pangaea Oncology, Barcelona*

17:25: CLOSING REMARKS



Cancer Biology and Precision Medicine Laboratory



For **FREE REGISTRATION**, email lourdes.franquet.oncology@gmail.com indicating your **full name** and **affiliation**

For more general information, here is the meeting web:

<http://www.germanstrias.org/events/159/iii-cancer-cell-signalling-pathways-conference>



How to get to the Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol

By car / taxi:

We are 20 minutes from the center of the city and the most convenient way to arrive is by car or taxi. We are close to the Hospital which can serve as a good point of reference:

Hospital Universitari Germans Trias I Pujol (Popularly known as Can Rutí)

GPS: 41°29'06.66"N 2°14'21.27"E

From Barcelona take B20 (Rondas and Nus de la Trinitat) in direction Mataró. The hospital is well signed from the exit 21 (Badalona Centre) of the B20.

With the collaboration of Lourdes Franquet and Stephanie Davis